Pulmatrix Q2 net loss $1.0M; cash $2.2M; merger with Eos on track for Q3 close

Pulmatrix, Inc.

Q2 net loss $1.036M ($0.29/share) vs $1.549M loss year ago; R&D expenses <$0.1M.
Cash and equivalents $2.2M plus $0.7M restricted; going concern assumption within one year.
Merger with Eos SENOLYTIX expected to close Q3 2026; Form S-4 filed July 9, amended Aug 3.
G&A expenses down to $1.0M from $1.5M; all clinical development on hold to license/monetize assets.
iSPERSE patent portfolio ~142 granted patents, 17 US; PUR1900 Phase 3 in India by Cipla.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.